EP0891337A1 - Inhibitors of farnesyl-protein transferase - Google Patents

Inhibitors of farnesyl-protein transferase

Info

Publication number
EP0891337A1
EP0891337A1 EP97917131A EP97917131A EP0891337A1 EP 0891337 A1 EP0891337 A1 EP 0891337A1 EP 97917131 A EP97917131 A EP 97917131A EP 97917131 A EP97917131 A EP 97917131A EP 0891337 A1 EP0891337 A1 EP 0891337A1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
alkyl
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917131A
Other languages
German (de)
French (fr)
Inventor
Samuel L. Graham
Neville J. Anthony
John S. Wai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614316.9A external-priority patent/GB9614316D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0891337A1 publication Critical patent/EP0891337A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Ras proteins are part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
  • Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein.
  • Ras In the inactive state, Ras is bound to GDP.
  • Ras Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change.
  • the GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, Ann. Rev. Biochem.
  • Mutated ras genes are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias.
  • the protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.
  • Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras.
  • the Ras C-terminus contains a sequence motif termed a "CAAX” or "Cys-Aaa 1 -Aaa 2 -Xaa” box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al, Nature 570:583-586 (1984)).
  • this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively.
  • farnesyl-protein transferase or geranylgeranyl-protein transferase which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively.
  • farnesylated proteins include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.
  • Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss et al, Cell, 62:81 -88 ( 1990); Schaber et al, J. Biol Chem., 265:14701-14704 (1990); Schafer et al, Science, 249: 1133-1 139 (1990); Marine et al, Proc. Natl Acad. Sci USA, 87:7541-7545 (1990)).
  • Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells.
  • direct inhibition of farnesyl- protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
  • FPTase farnesyl-protein transferase
  • FPP farnesyl diphosphate
  • Ras protein substrates
  • the peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation.
  • Such inhibitors may inhibit protein prenylation while serving as altemate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141 ,851, University of Texas; N.E. Kohl et al, Science, 260: 1934-1937 (1993); Graham, et al, J. Med. Chem., 37, 725 (1994)).
  • deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound.
  • the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.
  • FPTase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7-1 12930).
  • the present invention comprises peptidomimetic benzodiazepine-containing compounds which inhibit the famesyl-protein transferase.
  • the instant compounds lack a thiol moiety and thus offer unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity.
  • the compounds of this invention are useful in the inhibition of famesyl-protein transferase and the famesylation of the oncogene protein Ras.
  • the inhibitors of famesyl-protein transferase are illustrated by the formula:
  • Rb is selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, , R lS(0) m -, R10C(0)NR10-, (Rl0) 2 N-C(O)-, CN, N ⁇ 2, (R 10 )2N-C(NRlO)-, RlOC(O)-, RlO ⁇ C(O)-, -N(RlO)2, or Rl l ⁇ C(O)NRl0., c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 10 O-,
  • R 1 ⁇ (O , R 10 C(O)NRl0-, (Rl0) 2 N-C(O)-, CN, (RlO)2N-C(NRlO)-, RlOc(O)-, RlO ⁇ C(O)-, N3, -N(RlO)2, and Rl l ⁇ C(O)-NRl0-;
  • Rla and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, RlOO-, Rl l S(0) m -, R1°C(0)NR 10-, (R 0) 2 N- C(O)-, CN, N ⁇ 2, (R1°)2N-C(NR10)-, RK>C(0)-, R lO ⁇ C(O)-, N3, -N(RlO)2, or R l ⁇ C(O)NRl 0-, c) unsubstituted or substituted C 1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-, Rl
  • R 2 is selected from a) hydrogen, b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted -C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- Cio cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
  • R 1 ⁇ (O)TM-, Rl0C(O)NRl0-, (RlO)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, RiOC(O)-, RlO ⁇ C(O)-, N3, -N(RlO)2, and RUOC(O)-NR!0-;
  • R3 is selected from a sidechain of a natural amino acid
  • R 4 and R 4a are independently selected from: a) hydrogen, b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
  • R ⁇ is selected from : a) tetrazole, c) CONRlORlO;
  • R6 and R ⁇ a are independently selected from: a) hydrogen, b) halogen, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- CiO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-,
  • R8 is selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, RlOO-, RH S(0) m -, R10C(O)NR10-, CN, N02, Rl°2N-C(NRlO)-, RlOC(O)-, R lO ⁇ C(O)-, N3, -N(R lO)2, or RHOC(0)NR 10-, and c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, Rl o-, Rl lS(0) m -, R1°C(0)NH-, CN, H2N- C(NH)-, RlOc(O)-, RlO ⁇ C(O)-,
  • R9 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, RlOO-, Rl lS(0) m -, Rl°C(O)NR l0-, CN, N02, (R10) 2 N-C-(NR 10)-, R10 C (O)-, RlO ⁇ C(O)-, N3, -N(RlO)2, or Rl lOC(O)NRl0-, and c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, Rl o-, RHS(0) m -, R !
  • C(O)NR 10. CN, (RlO) 2 N-C(NRl )-, RlOc(O)-, RlO ⁇ C(O)-, N3, -N(Rl )2, or Rl 10C(0)NR10- ;
  • R IO i selected from hydrogen, Cl -C alkyl, benzyl and aryl;
  • Rl 1 is selected from -C6 alkyl and aryl
  • Q is selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-, RHS(0) m -, R 10 C(O)NRl0-, (Rl0) 2 N-C(O)-, CN, N ⁇ 2, (R 10 )2N-C(NRlO)-, RlOc(O)-, Rl oC(O)-, -N(Rl )2, or Rl l ⁇ C(O)NRl0-, c) unsubstituted or substituted Cl -C6 alkyl wherein the substitutent on the substituted -C alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6
  • V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m;
  • W is selected from: a) hydrogen, b) CF3, c) unsubstituted or substituted Cl -Cs alkyl wherein the substitutent on the substituted C1-C8 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- Cio cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R J 0 ⁇ -, R U S(0)m-, R 10 C(O)NRl0-, (RlO) 2 N-C(0)-, CN, (R10)2N-C(NR10)., R10C(O)-, Rl ⁇ C(O)-, N3, -N(RlO)2, and RHOC(0)-N 10- ; d) unsubstituted or substituted C1 -C8 cycloalkyl wherein the substitutent on the substituted C1-C8 cycloalkyl is selected from halogen, unsubsti
  • Ras farnesyl transferase inhibitors of formula I contain the following substituents:
  • Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
  • R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
  • R 4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C l -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-,
  • R5 is selected from: a) C02 0, wherein R 1 ° is hydrogen or C 1 -C6 alkyl and b) CONR 1 OR 10, wherein R 10 is hydrogen or C l -C6 alkyl.
  • Q is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl l S(0)m-, Rl0C(O)NR l0-, (RlO) 2 N-C(0)-, CN, N02, (RlO)2N-C(NRlO)-, RlOC(O)-, RlO ⁇ C(O)-, -N(RlO)2, or Rl l ⁇ C(0)NRl°-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from unsubstituted or substituted aryl, heterocycl
  • X is -CH2- ;
  • Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R lOO-, R 1 ⁇ (O , RlOC(0)NR l -, (RlO) 2 N-C(0)-, CN, (RlO)2N-C(NRlO)-, R lOC(O)-, RlO ⁇ C(O)-, N3, -N(R lO)2, and Rl l ⁇ C(O)-N l0- ;
  • R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
  • R 4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-, R ⁇ S(0) m -, Rl0c(O)NRl0-, (RlO) 2 N-C(0)-, CN, (RlO) 2 N-C(NRlO)-, RlOc(O)-, RlO ⁇ C(O)-, N3,
  • R5 is selected from: a) C02 10, wherein R 10 is hydrogen or C l -C alkyl and b) CONRlORlO, wherein R O is hydrogen or C1-C6 alkyl.
  • R9a is hydrogen or methyl
  • 0 is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl lS(0)m-, R1°C(0)NR10-, (RlO) 2 N-C(0)-, CN, N ⁇ 2, (RlO)2N-C(NRlO)-, RlOc(O)-, RlO ⁇ C(O)-, -N(Rl )2, or Rl lOC(O)NRl0-, c) unsubstituted or substituted C l -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-, R n S(0)m-, Rl°C(O)NRl0-
  • X is -CH2- ;
  • the inhibitors of famesyl-protein transferase are illustrated by the formula B:
  • Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, Rl lS(0) m -, RlOC(0)NRlO-, (Rl0) 2 N-C(O)-, CN, (RlO) 2 N-C(NR lO)-, RlOC(O)-, R lO ⁇ C(O)-, N3, -N(RlO) 2 , and RHOC(O)-I R 10- ;
  • R3 is selected from methionine,serine, glutamine, leucine and phenylalanine;
  • R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R ] 0 ⁇ -,
  • R 1 ⁇ (O) -, RlOC(0)NRlO-, (R l0) 2 N-C(O)-, CN, (R 10) 2 N-C(NR 10)., RlOc(O)-, RlO ⁇ C(O)-, N3, -N(Rl )2, and Rl l ⁇ C(O)-N l0- ;
  • R5 is selected from: a) CO2RIO, wherein R ° is hydrogen or Cl -C6 alkyl and b) CONRlORlO, wherein RlO is hydrogen or C1-C alkyl.
  • R8 is selected from: a) hydrogen, b) C 1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C l -C6 perfluoroalkyl, F, Cl, RlOO-, R!0C(O)NR 0-, CN, N02, (RlO) 2 N-C(NRlO)-, RlOc(O)-, Rl oC(O)-, -N(RlO)2, or Rl lOC(O)NRl0-, and c) C 1 -C6 alkyl substituted by C1-C6 perfluoroalkyl, Rl°0-, R 10C(O)NR 10., (R 10) 2N _C(NR 10 , R 10C(O)-, RlO ⁇ C(O)-, -N(RlO)2, or Rl lOC(0)NRlO-, d) unsubstituted or substituted aryl or hetero
  • Q is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl lS(0)m-, R!0C(O) R10-, (RlO) 2 N-C(0)-, CN, N02, (RlO)2N-C(NRl >, RlOc(O)-, RlO ⁇ C(O)-.
  • X is -CH2- ;
  • Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C 2 -C6 alkynyl, RlOO-,
  • R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
  • R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted Cl -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, R l l S(0)m-, Rl°C(O)NRl0-, (RlO) 2 N-C(0)-, CN, (R10) 2 N-C(NR 10)., RlOc(O)-, RlO ⁇ C(O)-, N3, -N(RlO)2, and RHOC(0)-NR10. ;
  • R5 is selected from: a) C02R 10, wherein R 1 ° is hydrogen or C 1 -C6 alkyl and b) CONRlORlO, wherein RlO is hydrogen or C1 -C6 alkyl;
  • 0 is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C 10 cycloalkyl, RlOO-, Rl lS(0) m -, R10C(O)NR10-, (Rl0)2N-C(O)-, CN, N02, (R!0)2N-C(NR10)-, RlOC(O)-, RlO ⁇ C(O)-, -N(RlO)2, or Rl l ⁇ C(O)NR l0-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-,
  • X is -CH2- ;
  • the preferred compounds of this invention include
  • amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below:
  • the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • cycloalkyl is intended to include non- aromatic cyclic hydrocarbon groups having the specified number of carbon atoms.
  • examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • alkenyl groups include those groups having the specified number of carbon atoms and having one or several double bonds. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like.
  • aryl is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic.
  • aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and the like.
  • heterocycle or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 1 1 - membered bicyclic or stable 11-15 membered tricyclic heterocycle ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydro ⁇ benzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazoly
  • substituted aryl As used herein, the terms “substituted aryl”, “substituted heterocycle” and “substituted cycloalkyl” are intended to include the cyclic group which is substituted with 1 or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(Cl -C6 alkyl)2, N02, CN, (Cl-C ⁇ alkyl)0-, -OH, (C1 -C6 alkyl)S(0)m-, (C1-C6 alkyl)C(0)NH-, H2N-C(NH)-, (C1 -C6 alkyl)C(O)-, (C1 -C6 alkyl)OC(O)-, N3,(Cl -C6 alkyl)OC(0)NH- and C1-C20 alkyl.
  • substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH
  • the pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenyl-acetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
  • any substituent or variable e.g., RlO, Z, n, etc.
  • -N(RlO) 2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth below.
  • the pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
  • the compounds of the invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, and the additional methods described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al, "The Peptides", Vol.
  • Such benzodiazepine analogs may be synthesized by techniques well known in the art. General methods of synthesis of the benzediazapine analogs of this invention are shown in Schemes 1 ,2 and 3. Typically a convergent route is employed, which joins the key intermediate 6 (Scheme 2) and R a and R D components (Schemes 2 and 3) using standard bond-forming procedures.
  • the amine 6 may be prepared from a suitably substituted 2-aminobenzoketone (2).
  • Many 2- aminobenzoketones are known in the art or are available form commercial sources such as Aldrich Chemical Co. General methods for the synthesis of new 2-aminobenzophenones (e.g Walsh, D. A. Synthesis, 677-688 (1980), Gates, M. J. Org. Chem 45, 1675, 1980,) and 2-aminobenzoketones may be found in the literature (e.g. Chambers,M.S, Bioorganic and Medicinal Chemistry, Vol 3, 1919 1993).
  • the amide 3 may be alkylated at N-l with an appropriate alkyl halide in the presense of a base such as cesium carbonate to afford the amide 4.
  • the amide 4 can be converted to the amine 6 via a two step protocol. Electrophillic azidination of the enolate anion generated by treatment of 4 with strong base such as sodium hexamethyl disilazide. with triisopropylbenzenesulfonylazide . Reduction of the azide by treatment of 5 with triphenylphosphine in aqueous THF affords the amine 6.
  • the amine 6 may be derivatized by acylation, reductive amination or alkylation to afford compounds of this invention (scheme 2). The syntheses of the required acylating, and alkylating reagents are shown in schemes 4, 5 and 6.
  • the instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer.
  • Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras activity (i.e., neurofibromin (NF-1), neu, ser, abl , lck, fyn) or by other mechanisms.
  • the compounds of the instant invention inhibit famesyl- protein transferase and the famesylation of the oncogene protein Ras.
  • the instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575- 4580 (1995)).
  • Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.
  • the compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment.
  • a component of NF-1 is a benign proliferative disorder.
  • the instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256:1331-1333 (1992).
  • the compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1 :541 -545(1995).
  • the instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffher et al. American Journal of Pathology, 142: 1051 -1060 (1993) and B. Cowley, Jr. et d ⁇ .FASEB Journal, 2:A3160 (1988)).
  • the instant compounds may also be useful for the treatment of fungal infections.
  • the compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
  • the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
  • carriers which are commonly used include lactose and com starch, and lubricating agents, such as magnesium stearate, are commonly added.
  • useful diluents include lactose and dried co starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
  • sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
  • the total concentration of solutes should be controlled in order to render the preparation isotonic.
  • the compounds of the instant invention may also be co- administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
  • the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents.
  • the instant compounds may be useful in combination with agents that are effective in the treatment and prevention of NF-1, restinosis, polycystic kidney disease, infections of hepatitis delta and related viruses and fungal infections.
  • Such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range.
  • Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
  • the present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.
  • suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacolo ⁇ gically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's blood-stream by local bolus injection.
  • the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
  • a suitable amount of compound is administered to a mammal undergoing treatment for cancer.
  • Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
  • the compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of famesyl-protein transferase (FPTase) in a composition.
  • FPTase famesyl-protein transferase
  • the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention.
  • the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.
  • potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample.
  • a series of samples composed of aliquots of a tissue extract containing an unknown amount of famesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention.
  • concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
  • concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
  • Step A l -Triphenylmethyl-4-(hydroxymethvD-imidazole
  • Step B l-Triphenylmethyl-4-(acetoxymethyl -imidazole
  • Step C l-(4-Cyanobenzyl)-5-(acetoxymethyl)-imidazole hydrobromide
  • the filtrate was concentrated in vacuo to a volume 100 mL, reheated at 60 °C for another two hours, cooled to room temperature, and concentrated in vacuo to provide a solid. All of the solid material was combined, dissolved in 500 mL of methanol, and warmed to 60 °C. After two hours, the solution was reconcentrated in vacuo to provide a solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a solid which was used in the next step without further purification.
  • Step D l-(4-CvanobenzylV5-( ' hvdroxymethylVimidazole
  • Step C To a solution of the acetate from Step C (50.4 g, 150 mmol) in 1.5 L of 3: 1 THF/water at 0 °C was added lithium hydroxide monohydrate (18.9 g, 450 mmol). After one hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 L), and washed with water, sat. aq. NaHC ⁇ 3 and brine. The solution was then dried (Na2S04), filtered, and concentrated in vacuo to provide the crude product as a solid which was sufficiently pure for use in the next step without further purification.
  • Step E l -(4-Cyanobenzyl)-5-imidazolecarboxaldehyde
  • Step F 2.3-Dihydro-2-oxo-5-phenyl-lH-1.4-benzo-diazepine ⁇
  • Step G 2,3-Dihydro- l -(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-lH-
  • Step H 3-Azido-5-phenyl-l-(2,2,2-trifluoroethyl)-lH- benzorel ⁇ 1.41 diazepine
  • Step J 2-(R)-2-amino-N-[3R-2-oxo-5- ⁇ henyl- 1 - (2,2,2- trifluoroethyl)-2,3-dihydro-lH-benzo[e][l,41diazepin-3- yl]-3-phenyl-propionamide and 2-(R)-2-amino-N-[3(S)-2- oxo-5-phenyl-l - (2,2,2-trifluoroethyl)-2,3-dihydro-lH- benzoielf 1 ,41diazepin-3-yll-3-phenyl-propionamide
  • Step K 3-(R)-(+)-3-amino-5-phenyl- 1 -(2,2,2-trifluoro- ethyl)-H- benzof el ⁇ 1 ,41 diazepine
  • Step L 3S-(+)-3-Amino-5-phenyl-l-(2,2,2-trifluoro-ethyl)-H- benzorei ⁇ .41 diazepine
  • Step M 3(R)-3- ⁇ l-(4-Cyanobenzyl)imidazol-5-yl-methylamino ⁇ - 5-phenyl- 1 -(2.2.2-trifluoroethyl)-H-benzof el f 1.41 diazepine
  • stepK 3(R)-3- ⁇ l-(4-Cyanobenzyl)imidazol-5-yl-methylamino ⁇ - 5-phenyl- 1 -(2.2.2-trifluoroethyl)-H-benzof el f 1.41 diazepine
  • stepK 99.8mg, 0.299mmol
  • the aldehyde from example 1, step E
  • Step A lH-Imidazole-4- acetic acid methyl ester hydrochloride
  • Step B 1 -(Triphenylmethyl)- lH-imidazol-4-ylacetic acid methyl ester
  • Step C [1 -(4-cyanobenzyl)- 1 H-imidazol-5-yl]acetic acid methyl ester
  • Step D ⁇ 1 -(4-CvanobenzylV lH-imidazol-5-yllacetic acid
  • Step E 3(R)-3- ⁇ l-(4-Cyanobenzyl) iinidazol-5-yl-acety]amino ⁇ -5- phenyl- 1 -C2.2.2-trifluoroethyl)-H-benzofel ⁇ 1.41 diazepine
  • 3(R)-(+)-3-amino-5-phenyl- l -(2,2,2- trifluoroethyl)-H-benzo[el[l ,4] diazepine from example 1 , step K) (100.5mg, 0.302mmol), [ l -(4-cyanobenzyl)-lH-imidazol-5-yl]acetic acid (from step D) (85.9mg, O.303mmol), HOOBT (60.4mg, O.37mmol) and triethylamine (0.10ml, 0.717mmol) in DMF (3ml) was added EDC
  • a solution of 3-amino-2,3-dihydro-2-oxo-5-phenyl-lH -1 ,4 -benzodiazepine hydrogen bromide (142 mg, 0.426 mmol), prepared by sequential treatment of an aqueous acetonitrile solution of the 4-methoxybenzyl derivative from example 5 with ammonium cerium IV nitrate, potassium tartrate solution and HBr/acetic acid - ( )- pyroglutamic acid (60.2 mg, 0.466 mmol), EDC (91 mg, 0.473 mmol), HOBT (63.5 mg, 0.473 mmol), and diisopropylethylamine (0.082ml, 0.473 mmol) in DMF (5 ml) was stirred at room temperature for 1 hours.
  • step C To a stirred solution of the ester from example 3, step C, (1.50g, 5.88mmol), in methanol (20ml) at 0°C, was added sodium borohydride (l.Og, 26.3mmol) portionwise over 5 minutes. The reaction was stirred at 0°C for 1 hr and then at room temperature for an additional 1 hr. The reaction was quenched by the addition of sat.NH4Cl solution and the methanol evaporated in vacuo. The residue wsas partitioned between EtOAc and sat NaHC ⁇ 3 solution and the organic extracts dried (MgS04) and evaporated in vacuo.
  • Step B 5-(-l -(4-Cvanobenzyl)-imidazolv ⁇ ethyl methanesulfonate
  • a solution of 5-[l-(4-cyanobenzyl)-lH-imidazolyl]ethanol (0.500 g, 2.20 mmol) in methylene chloride (6 ml) at 0°C was treated with Hunig's base (0.460ml, 2.64mmol) and methane sulfonyl chloride (0.204ml, 2.64mmol).
  • Step C 3(R)-3-f l-(4-Cyanobenzyl) imidazol-5-yl-ethylamino- ⁇ -5- phenyl-1 -(2.2.2-trifluoroethyD-H-benzo[e1f 1.41 diazepine
  • a mixture of 3R-(+)-3-amino-5-phenyl-l -(2,2,2- trifluoroethyl)-H-benzo[el[l ,4] diazepine from example 1 , step K) (99.5mg, 0.299mmol), 5-(-l -(4-Cyanobenzyl)-imidazolyl)ethyl methanesulfonate (from step B) (94.5mg, 0.309mmol), K2CO3 (108mg,
  • Partially purified bovine FPTase and Ras peptides were prepared as described by Schaber et al, J. Biol Chem. 265.14701-14704 (1990), Pompliano, et al, Biochemistry 57 :3800 (1992) and Gibbs et al, PNAS U.S.A. #6:6630-6634 (1989), respectively.
  • Bovine FPTase was assayed in a volume of 100 ⁇ l containing 100 mM N-(2-hydroxy ethyl) piperazine- V'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM [3Hj-famesyl diphosphate ([3H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 ⁇ g/ml FPTase at 31 °C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol.
  • Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB ⁇ -plate counter.
  • the assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [3HJ-FPP was utilized during the reaction period.
  • Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
  • DMSO dimethyl sulfoxide
  • Human FPTase was prepared as described by Omer et al, Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1 % (w/v) polyethylene glycol 20,000, 10 ⁇ M ZnCl 2 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 ⁇ l of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme. The compounds of the instant invention described in Examples 1 -10 were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC50 of ⁇ 100 ⁇ M.
  • the cell line used in this assay is a v-ras line derived from either Ratl or NIH3T3 cells, which expressed viral Ha-ras p21.
  • the assay is performed essentially as described in DeClue, J.E. et al, Cancer Research 57:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%).
  • the cells After 4 hours at 37 °C, the cells are labelled in 3 ml methionine-free DMEM supple- meted with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[35s]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupe ⁇ tin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min.
  • 1 ml lysis buffer 1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupe ⁇ tin/2 mg/ml antipain/0.5 mM
  • the immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X- 100.0.5% deoxycholate/0.1 %/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein.
  • IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X- 100.0.5% deoxycholate/0.1 %/SDS/0.1 M NaCl
  • Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x IO 4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1 % methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay).
  • the cells are fed twice weekly with 0.5 ml of medium A containing 0.1 % memanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to substituted benzodiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Description

TITLE OF THE INVENTION
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
BACKGROUND OF THE INVENTION
The Ras proteins (Ha-Ras, Ki4a-Ras, Ki4b-Ras and N-Ras) are part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP. Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, Ann. Rev. Biochem. 62:851 -891 (1993)). Mutated ras genes (Ha-ras, Ki4a-røs, Ki4b-ras and N-ras) are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.
Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed a "CAAX" or "Cys-Aaa1-Aaa2-Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al, Nature 570:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively. (S. Clarke., Ann. Rev. Biochem. 67 :355-386 (1992); W.R. Schafer and J. Rine, Ann. Rev. Genetics 30:209-237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational famesylation. Other farnesylated proteins include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.
Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and to modify other aspects of their transformed phenotype. It has also been demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly (N.E. Kohl et al., Science, 260:1934-1937 (1993) and G.L. James et al., Science, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of farnesyl-protein transferase blocks the growth of ras- dependent tumors in nude mice (N.E. Kohl et al, Proc. Natl Acad. Sci U.S.A., 97:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in ras transgenic mice (N.E. Kohl et al, Nature Medicine, 1 :792-797 (1995).
Indirect inhibition of farnesyl-protein transferase in vivo has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock et al, ibid; Casey et al, ibid; Schafer et al, Science 245:319 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including farnesyl pyrophosphate. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss et al, Cell, 62:81 -88 ( 1990); Schaber et al, J. Biol Chem., 265:14701-14704 (1990); Schafer et al, Science, 249: 1133-1 139 (1990); Marine et al, Proc. Natl Acad. Sci USA, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of farnesyl- protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
Inhibitors of farnesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of farnesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrates (e.g., Ras) for the enzyme. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber et al, ibid; Reiss et. al, ibid; Reiss et al, PNAS, #c?:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as altemate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141 ,851, University of Texas; N.E. Kohl et al, Science, 260: 1934-1937 (1993); Graham, et al, J. Med. Chem., 37, 725 (1994)). In general, deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound. However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.
It has recently been reported that FPTase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7-1 12930).
It is, therefore, an object of this invention to develop peptidomimetic compounds that do not have a thiol moiety, and that will inhibit famesyl-protein transferase and thus, the post-translational famesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention. SUMMARY OF THE INVENTION
The present invention comprises peptidomimetic benzodiazepine-containing compounds which inhibit the famesyl-protein transferase. The instant compounds lack a thiol moiety and thus offer unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
The compounds of this invention are illustrated by the formula:
(I)
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention are useful in the inhibition of famesyl-protein transferase and the famesylation of the oncogene protein Ras. In one embodiment of this invention, the inhibitors of famesyl-protein transferase are illustrated by the formula:
(0
wherein: R is
V - A1(CR1 a 2)nA2(CR1 a 2)n (CR1 b 2 2)ή, -X-Ϊ
Rb is selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, , R lS(0)m-, R10C(0)NR10-, (Rl0)2N-C(O)-, CN, Nθ2, (R10)2N-C(NRlO)-, RlOC(O)-, RlOθC(O)-, -N(RlO)2, or Rl lθC(O)NRl0., c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 ^(O , R10C(O)NRl0-, (Rl0)2N-C(O)-, CN, (RlO)2N-C(NRlO)-, RlOc(O)-, RlOθC(O)-, N3, -N(RlO)2, and Rl lθC(O)-NRl0-;
Rla and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, RlOO-, Rl l S(0)m-, R1°C(0)NR 10-, (R 0)2N- C(O)-, CN, Nθ2, (R1°)2N-C(NR10)-, RK>C(0)-, R lOθC(O)-, N3, -N(RlO)2, or R lθC(O)NRl 0-, c) unsubstituted or substituted C 1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-, Rl lS(0)m-, Rl0C(O)NRl0-, (R10)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, RlOC(O)-, RlOθC(O)-, N3, -NCR10)2, and Rl lθC(O)-NRl0-;
R2 is selected from a) hydrogen, b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted -C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- Cio cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
R1 ^(O)™-, Rl0C(O)NRl0-, (RlO)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, RiOC(O)-, RlOθC(O)-, N3, -N(RlO)2, and RUOC(O)-NR!0-;
R3 is selected from a sidechain of a natural amino acid;
R4 and R4a are independently selected from: a) hydrogen, b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
Rl lS(0)m-, R10C(O)NR10-, (RlO) N-C(0)-, CN, (R1°)2N-C(NR10)-, RlOC(O)-, RlOθC(O)-, N3, -N(RlO)2, and RHOC(O)-NR 10-;
R^ is selected from : a) tetrazole, c) CONRlORlO; R6 and R^a are independently selected from: a) hydrogen, b) halogen, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- CiO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-,
Rl l S(0)m-, Rl c(O)NRl0-, (Rl0)2N-C(O)-, CN, (RlO)2N-C(NRlO)-, RlOC(O)-, RlOθC(O)-, N3, -N(RlO)2, and Rl 10C(0)-NR10-;
R8 is selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, RlOO-, RH S(0)m-, R10C(O)NR10-, CN, N02, Rl°2N-C(NRlO)-, RlOC(O)-, R lOθC(O)-, N3, -N(R lO)2, or RHOC(0)NR 10-, and c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, Rl o-, Rl lS(0)m-, R1°C(0)NH-, CN, H2N- C(NH)-, RlOc(O)-, RlOθC(O)-, N3, -N(RlO)2, or Rl0θC(O)NH-;
R9 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, RlOO-, Rl lS(0)m-, Rl°C(O)NR l0-, CN, N02, (R10)2N-C-(NR 10)-, R10C(O)-, RlOθC(O)-, N3, -N(RlO)2, or Rl lOC(O)NRl0-, and c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, Rl o-, RHS(0)m-, R ! C(O)NR 10., CN, (RlO)2N-C(NRl )-, RlOc(O)-, RlOθC(O)-, N3, -N(Rl )2, or Rl 10C(0)NR10-; R IO i selected from hydrogen, Cl -C alkyl, benzyl and aryl;
Rl 1 is selected from -C6 alkyl and aryl;
A and A2 are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NRl0-, -NRlOC(O)-, O, -N(R10)-, -S(0)2N(RlO)-, -N(Rl0)S(O)2-, or S(0)m;
Q is selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-, RHS(0)m-, R10C(O)NRl0-, (Rl0)2N-C(O)-, CN, Nθ2, (R10)2N-C(NRlO)-, RlOc(O)-, Rl oC(O)-, -N(Rl )2, or Rl lθC(O)NRl0-, c) unsubstituted or substituted Cl -C6 alkyl wherein the substitutent on the substituted -C alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, RπS(0)m-, R10C(O)NRl0-, (R10)2N-C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, RlOθC(O)-, N3, -N(RlO)2, and Rl lθC(0)-NR10-;
V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A2 is S(0)m;
W is selected from: a) hydrogen, b) CF3, c) unsubstituted or substituted Cl -Cs alkyl wherein the substitutent on the substituted C1-C8 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- Cio cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R J0θ-, RUS(0)m-, R10C(O)NRl0-, (RlO)2N-C(0)-, CN, (R10)2N-C(NR10)., R10C(O)-, Rl θC(O)-, N3, -N(RlO)2, and RHOC(0)-N 10-; d) unsubstituted or substituted C1 -C8 cycloalkyl wherein the substitutent on the substituted C1-C8 cycloalkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, Rl lS(0)m-, R10C(O)NRl0-, (R 1°)2N- C(O)-, CN, (RlO)2N-C(NR O)-, RlOC(O)-, RlOθC(O)-, N3, -N(R 10)2, and Rl lθC(O)-NRl0-; e) unsubstituted or substituted heterocycle, f) unsubstituted or substituted aryl, and g) CON(R2)CR3R5 or R4, R4a an(j w taken together are hydrogen;
X is -CH2-, -C(=0)-, or -S(=0)m-;
or the pharmaceutically acceptable salts thereof. In a preferred embodiment of this invention, the Ras farnesyl transferase inhibitors of formula I contain the following substituents:
Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
R1 lS(0)m-, Rl°C(O)NRl0-, (R10)2N-C(0)-, CN, (RlO) N-C(NRl )-, RlOc(O)-, RlOθC(O)-, N3, -N(Rl )2, and R 1 10C(0)-NR 10-;
R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C l -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-,
Rl lS(0)m-, R!0C(O)NR10-, (Rl0)2N-C(O)-, CN, (R10)2N-C(NR10)-, RlOc(O)-, RlOθC(O)-, N3, -N(Rl )2, and Rl 10C(0)-NR10-;
R5 is selected from: a) C02 0, wherein R 1 ° is hydrogen or C 1 -C6 alkyl and b) CONR 1 OR 10, wherein R 10 is hydrogen or C l -C6 alkyl. Q is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl l S(0)m-, Rl0C(O)NR l0-, (RlO)2N-C(0)-, CN, N02, (RlO)2N-C(NRlO)-, RlOC(O)-, RlOθC(O)-, -N(RlO)2, or Rl lθC(0)NRl°-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1 -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-,
Rl lS(0)m-, Rl C(0)NRlO-, (Rl0)2N-C(O)-, CN, (RlO)2N-C(NRlO)-, R10C(O)-, Rl°OC(0)-, N3, -N(RlO)2, and RHOC(0)-NR 1°-; and
X is -CH2- ;
or the pharmaceutically acceptable salts thereof.
A preferred embodiment of the compounds of this invention are illustrated by the formula A:
wherein:
Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R lOO-, R1 ^(O , RlOC(0)NR l -, (RlO)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, R lOC(O)-, RlOθC(O)-, N3, -N(R lO)2, and Rl lθC(O)-N l0-;
R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl O-, RπS(0)m-, Rl0c(O)NRl0-, (RlO)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, RlOc(O)-, RlOθC(O)-, N3,
-N(R 10)2, and R 11 OC(0)-NR 10.;
R5 is selected from: a) C02 10, wherein R 10 is hydrogen or C l -C alkyl and b) CONRlORlO, wherein R O is hydrogen or C1-C6 alkyl.
R9a is hydrogen or methyl;
0 is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl lS(0)m-, R1°C(0)NR10-, (RlO)2N-C(0)-, CN, Nθ2, (RlO)2N-C(NRlO)-, RlOc(O)-, RlOθC(O)-, -N(Rl )2, or Rl lOC(O)NRl0-, c) unsubstituted or substituted C l -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-, RnS(0)m-, Rl°C(O)NRl0-, (R10)2N-C(O)-, CN, (R 10)2N-C(NR 10)-, RlOC(O)-, RlOθC(O)-, N3, -N(R lO)2, and RH OC(0)-NR 1 -; and
X is -CH2- ;
or the pharmaceutically acceptable salts thereof.
In a more preferred embodiment of this invention, the inhibitors of famesyl-protein transferase are illustrated by the formula B:
wherein:
Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, Rl lS(0)m-, RlOC(0)NRlO-, (Rl0)2N-C(O)-, CN, (RlO)2N-C(NR lO)-, RlOC(O)-, R lOθC(O)-, N3, -N(RlO)2, and RHOC(O)-I R 10-;
R3 is selected from methionine,serine, glutamine, leucine and phenylalanine; R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R]0θ-,
R1 ^(O) -, RlOC(0)NRlO-, (R l0)2N-C(O)-, CN, (R 10)2N-C(NR 10)., RlOc(O)-, RlOθC(O)-, N3, -N(Rl )2, and Rl lθC(O)-N l0-;
R5 is selected from: a) CO2RIO, wherein R ° is hydrogen or Cl -C6 alkyl and b) CONRlORlO, wherein RlO is hydrogen or C1-C alkyl.
R8 is selected from: a) hydrogen, b) C 1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C l -C6 perfluoroalkyl, F, Cl, RlOO-, R!0C(O)NR 0-, CN, N02, (RlO)2N-C(NRlO)-, RlOc(O)-, Rl oC(O)-, -N(RlO)2, or Rl lOC(O)NRl0-, and c) C 1 -C6 alkyl substituted by C1-C6 perfluoroalkyl, Rl°0-, R 10C(O)NR 10., (R 10)2N_C(NR 10 , R 10C(O)-, RlOθC(O)-, -N(RlO)2, or Rl lOC(0)NRlO-, d) unsubstituted or substituted aryl or heterocycle;
Q is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C10 cycloalkyl, RlOO-, Rl lS(0)m-, R!0C(O) R10-, (RlO)2N-C(0)-, CN, N02, (RlO)2N-C(NRl >, RlOc(O)-, RlOθC(O)-. -N(RlO)2, or Rl lθC(O)NRl0-, c) unsubstituted or substituted Cl -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R l O-, RnS(0)m-, Rl°C(O)NRl0., (Rl0)2N-C(O)-, CN, (R 10)2N-C(NR 10)-, RlOc(O)-, RlOθC(O)-, N3, -N(Rl )2, and RH OC(O)-NR10-; and
X is -CH2- ;
or the pharmaceutically acceptable salts thereof.
In a second more preferred embodiment of this invention, the inhibitors of famesyl-protein transferase are illustrated by the formula C:
wherein:
Rb is selected from: a) hydrogen, and b) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-,
R 1 1 S(0)m-, R 1 °C(0)NR 10., (R 10)2N-C(O)-, CN, (Rl0)2N-C(NRl0)-, Rl0c(O)-, RlOθC(O)-, N3, -N(R 10)2, and R 11 OC(0)-NR 10-; R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
R4 and R4a are independently selected from: a) hydrogen, and b) unsubstituted or substituted Cl -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-, R l l S(0)m-, Rl°C(O)NRl0-, (RlO)2N-C(0)-, CN, (R10)2N-C(NR 10)., RlOc(O)-, RlOθC(O)-, N3, -N(RlO)2, and RHOC(0)-NR10.;
R5 is selected from: a) C02R 10, wherein R 1 ° is hydrogen or C 1 -C6 alkyl and b) CONRlORlO, wherein RlO is hydrogen or C1 -C6 alkyl;
0 is selected from: a) hydrogen b) substituted or unsubstituted aryl, C3-C 10 cycloalkyl, RlOO-, Rl lS(0)m-, R10C(O)NR10-, (Rl0)2N-C(O)-, CN, N02, (R!0)2N-C(NR10)-, RlOC(O)-, RlOθC(O)-, -N(RlO)2, or Rl lθC(O)NR l0-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RlOO-,
Rl lS(0)m-, RlOC(0)NRlO-, (RlO)2N-C(0)-, CN, (RlO)2N-C(NRlO)-, RlOC(O)-, RlOθC(O)-, N3, -N(Rl )2, and Rl lθC(O)-NR l0-; and
X is -CH2- ;
or the pharmaceutically acceptable salts thereof. The preferred compounds of this invention include
3(R)-3-[ l-(4-Cyanobenzyl)imidazol-5-yl-methylamino]-5-phenyl-l - (2,2,2-trifluoroethyl)-H-benzoie][ 1 ,4] diazepine;
3(S)-3-[l-(4-Cyanobenzyl)imidazol-5-yl-methylamino]-5-phenyl-l - (2,2,2-trifluoroethyl)-H-benzo[e]f 1 ,4] diazepine;
3(R)-3-[l-(4-Cyanobenzyl)imidazol-5-yl-acetylaminoJ-5-phenyl-l- (2,2,2-trifluoroethyl)-H-benzo[e] f 1 ,4] diazepine;
3(S)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-acetylamino]-5-phenyl- 1 - (2,2,2-trifluoroethyl)-H-benzo[el[l ,4] diazepine;
3(R,S)-3-[ l-(4-Cyanobenzyl)imidazol-5-yl-acetylamino]-5-phenyl-l -(4- methoxy benzyl)-H-benzole][l,41 diazepine;
3(R)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-acetylamino]-5-phenyl- 1 - (methyl)-H-benzo[el[ 1 ,4] diazepine;
3(R)-3-f 1 -(4-Cyanobenzyl) imidazol-5-yl-acetylamino]-5-(4- fluorophenyl-1 -(2,2,2 trifluoroethyl)-H-benzo[e][l,41 diazepine;
3-[5-Oxo-pyrrolidine-2(S)-carbonylamino]-2,3-dihydro-2-oxo-5- phenyl-lH -1,4-benzodiazepine;
3(R)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-ethylaminol-5-phenyl- 1 -(2,2,2- trifluoroethyl)-H-benzo[e][ l ,4] diazepine; and
3(S)-3-[ 1 -(4-Cyanobenzyl) imidazol-5-yl]-ethylaminol-5-phenyl- 1 - (2,2,2-trifluoroethyl)-H-benzo[e] [ 1 ,4J diazepine. Specific examples of the compounds of the invention include
3(S)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-y l-ethylamino]-5-phenyl- 1 -(2,2,2- trifluoroethyl)-H-benzo[el[l ,41 diazepine; and
3(R)-3-[ 1 -(4-Cyanobenzyl) imidazol-5-yl-ethylamino]-5-phenyl- 1 - (2,2,2-trifluoroethyl)-H-benzo[e][ 1 ,41 diazepine
In the present invention, the amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below:
The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
As used herein, "cycloalkyl" is intended to include non- aromatic cyclic hydrocarbon groups having the specified number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
"Alkenyl" groups include those groups having the specified number of carbon atoms and having one or several double bonds. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like.
As used herein, "aryl" is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and the like.
The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 1 1 - membered bicyclic or stable 11-15 membered tricyclic heterocycle ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydro¬ benzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyridonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolinyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl.
As used herein, the terms "substituted aryl", "substituted heterocycle" and "substituted cycloalkyl" are intended to include the cyclic group which is substituted with 1 or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(Cl -C6 alkyl)2, N02, CN, (Cl-Cό alkyl)0-, -OH, (C1 -C6 alkyl)S(0)m-, (C1-C6 alkyl)C(0)NH-, H2N-C(NH)-, (C1 -C6 alkyl)C(O)-, (C1 -C6 alkyl)OC(O)-, N3,(Cl -C6 alkyl)OC(0)NH- and C1-C20 alkyl.
The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenyl-acetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
It is intended that the definition of any substituent or variable (e.g., RlO, Z, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, -N(RlO)2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth below.
The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents. The compounds of the invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, and the additional methods described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al, "The Peptides", Vol. I, Academic Press 1965, or Bodanszky et al, "Peptide Synthesis", Interscience Publishers, 1966, or McOmie (ed.) "Protective Groups in Organic Chemistry", Plenum Press, 1973, or Barany et al, "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, or Stewart et al, "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.
Abbreviations used in the description of the chemistry and in the Examples that follow are:
Ac2θ Acetic anhydride;
Boc t-Butoxycarbonyl;
DBU 1 ,8-diazabicyclo[5.4.01undec-7-ene;
DMAP 4-Dimethylaminopyridine;
DME 1 ,2-Dimethoxyethane;
DMF Dimethylformamide;
EDC 1 -(3-dimethylaminopropyl)-3-ethyl-carbodiimide-HCl;
HOBT 1-Hydroxybenzotriazole hydrate;
Et3N Triethylamine;
EtOAc Ethyl acetate;
FAB Fast atom bombardment;
HOOBT 3 -Hydroxy- 1 ,2,2-benzotriazin-4(3//)-one;
HPLC High-performance liquid chromatography;
MCPBA m-Chloroperoxybenzoic acid;
MsCI Methanesulfonyl chloride;
NaHMDS Sodium bis(trimethylsilyl)amide;
Py Pyridine;
TFA Trifluoroacetic acid;
THF Tetrahydrofuran. Compounds of this invention are prepared by employing the reactions shown in Reaction Schemes 1 to 6 in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures.
SCHEME 1
H2
SCHEME 2
6 Q
SCHEME 3
CBZCI
NHCBZ
SCHEME 4
20 21
1. ArCH.XCH CN 55°C 2. CH3OH, reflux 22
23 24
SCHEME 5
23 25
25 26
30
29
31 32
REACTION SCHEME 7
NaBH4 (excess)
REACTION SCHEME 9
NaBH4 (excess)
REACTION SCHEME 10
excess NaBH4
Such benzodiazepine analogs may be synthesized by techniques well known in the art. General methods of synthesis of the benzediazapine analogs of this invention are shown in Schemes 1 ,2 and 3. Typically a convergent route is employed, which joins the key intermediate 6 (Scheme 2) and Ra and RD components (Schemes 2 and 3) using standard bond-forming procedures.
As shown in Scheme 1 , the amine 6 may be prepared from a suitably substituted 2-aminobenzoketone (2). Many 2- aminobenzoketones are known in the art or are available form commercial sources such as Aldrich Chemical Co. General methods for the synthesis of new 2-aminobenzophenones (e.g Walsh, D. A. Synthesis, 677-688 (1980), Gates, M. J. Org. Chem 45, 1675, 1980,) and 2-aminobenzoketones may be found in the literature (e.g. Chambers,M.S, Bioorganic and Medicinal Chemistry, Vol 3, 1919 1993).
Acylation of 2 with an haloacetyl halide, followed by treatment with ammonia in methanol gives the 1 ,4-benzodiazepin-2-one 3. The amide 3 may be alkylated at N-l with an appropriate alkyl halide in the presense of a base such as cesium carbonate to afford the amide 4.
The amide 4 can be converted to the amine 6 via a two step protocol. Electrophillic azidination of the enolate anion generated by treatment of 4 with strong base such as sodium hexamethyl disilazide. with triisopropylbenzenesulfonylazide . Reduction of the azide by treatment of 5 with triphenylphosphine in aqueous THF affords the amine 6. The amine 6 may be derivatized by acylation, reductive amination or alkylation to afford compounds of this invention (scheme 2). The syntheses of the required acylating, and alkylating reagents are shown in schemes 4, 5 and 6.
Syntheses of alternatively functionalized benzodiazepines are shown in scheme 3. Protection of the amide 3 with a 4-methoxy benzyl group allows the 3-amino group to be introduced efficiently. Subsequent deprotection of the amide and alkylation with a suitably protected bromoacetate for example methyl bromoacetate can afford compound 15. Hydrolysis of the ester and amide bond formation with the amine NH(R2)R3R5 can give the amide 17. For compounds where Rb ≠H, 17 (scheme 3) can be alkylated at N-3 with a wide variety of alkylating agents according to the standard procedure of Benoiton, et al., Can. J. Chem. 1977, 55, 906. to give 18. The amine 18 can be acylated or alkylated to afford compounds of this invention (for example 19).
Schemes 7- 10 illustrate syntheses of suitably substituted aldehydes useful in the syntheses of the instant compounds wherein the variable W is present as a pyridyl moiety. Similar synthetic strategies for preparing alkanols that incorporate other heterocyclic moieties for variable W are also well known in the art.
The instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras activity (i.e., neurofibromin (NF-1), neu, ser, abl , lck, fyn) or by other mechanisms.
The compounds of the instant invention inhibit famesyl- protein transferase and the famesylation of the oncogene protein Ras. The instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575- 4580 (1995)). Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.
The compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment. For example, a component of NF-1 is a benign proliferative disorder. The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256:1331-1333 (1992).
The compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1 :541 -545(1995).
The instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffher et al. American Journal of Pathology, 142: 1051 -1060 (1993) and B. Cowley, Jr. et dλ.FASEB Journal, 2:A3160 (1988)).
The instant compounds may also be useful for the treatment of fungal infections.
The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and com starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried co starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.
The compounds of the instant invention may also be co- administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Similarly, the instant compounds may be useful in combination with agents that are effective in the treatment and prevention of NF-1, restinosis, polycystic kidney disease, infections of hepatitis delta and related viruses and fungal infections.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacolo¬ gically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's blood-stream by local bolus injection.
When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of famesyl-protein transferase (FPTase) in a composition. Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to famesylate the substrate, the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.
It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain famesyl-protein transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of famesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor (i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.
EXAMPLES
Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.
EXAMPLE 1
Preparation of 3(R)-3-{[l-(4-Cyanobenzyl)imidazol-5-yl- methylaminol } -5-phenyl-l -(2,2,2-trifluoroethyl)-H-benzo[el[ 1 ,4] diazepine.
Step A: l -Triphenylmethyl-4-(hydroxymethvD-imidazole
To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35.0 g, 260 mmol) in 250 mL of dry DMF at room temperature was added triethylamine (90.6 mL, 650 mmol). A solid precipitated from the solution. Chlorotriphenylmethane (76.1 g, 273 mmol) in 500 mL of DMF was added dropwise. The reaction mixture was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a solid which was sufficiently pure for use in the next step.
Step B: l-Triphenylmethyl-4-(acetoxymethyl -imidazole
Alcohol from Step A (260 mmol, prepared above) was suspended in 500 mL of pyridine. Acetic anhydride (74 mL, 780 mmol) was added dropwise, and the reaction was stirred for 48 hours during which it became homogeneous. The solution was poured into 2L of EtOAc, washed with water (3 x 1 L), 5% aq. HCl soln. (2 x 1 L), sat. aq. NaHC03, and brine, then dried (Na2S04), filtered, and concentrated in vacuo to provide the crude product. The acetate was isolated as a powder which was sufficiently pure for use in the next reaction.
Step C: l-(4-Cyanobenzyl)-5-(acetoxymethyl)-imidazole hydrobromide
A solution of the product from Step B (85.8 g, 225 mmol) and α-bromo-/?-tolunitrile (50.1 g, 232 mmol) in 500 mL of EtOAc was stirred at 60 °C for 20 hours, during which a precipitate formed. The reaction was cooled to room temperature and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume 200 mL, reheated at 60 °C for two hours, cooled to room temperature, and filtered again. The filtrate was concentrated in vacuo to a volume 100 mL, reheated at 60 °C for another two hours, cooled to room temperature, and concentrated in vacuo to provide a solid. All of the solid material was combined, dissolved in 500 mL of methanol, and warmed to 60 °C. After two hours, the solution was reconcentrated in vacuo to provide a solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a solid which was used in the next step without further purification.
Step D: l-(4-CvanobenzylV5-('hvdroxymethylVimidazole
To a solution of the acetate from Step C (50.4 g, 150 mmol) in 1.5 L of 3: 1 THF/water at 0 °C was added lithium hydroxide monohydrate (18.9 g, 450 mmol). After one hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 L), and washed with water, sat. aq. NaHCθ3 and brine. The solution was then dried (Na2S04), filtered, and concentrated in vacuo to provide the crude product as a solid which was sufficiently pure for use in the next step without further purification. Step E: l -(4-Cyanobenzyl)-5-imidazolecarboxaldehyde
To a solution of the alcohol from Step D (21.5 g, 101 mmol) in 500 mL of DMSO at room temperature was added triethylamine (56 mL, 402 mmol), then Sθ3-pyridine complex (40.5 g, 254 mmol). After 45 minutes, the reaction was poured into 2.5 L of EtOAc, washed with water (4 x 1 L) and brine, dried (Na2Sθ4), filtered, and concentrated in vacuo to provide the aldehyde as a powder which was sufficiently pure for use without further purification.
Step F: 2.3-Dihydro-2-oxo-5-phenyl-lH-1.4-benzo-diazepine^
To a stirring solution of 2-aminobenzophenone (50 g, 0.25 mole) in methylene chloride (1 L) was added bromoacetyl bromide (58.0 g, 0.25 mole). An ice water bath was applied to maintain reaction temperature at <30°C. Sodium hydroxide (250 mL of a 3 N solution) was then added over 10 minutes and the cooling bath removed. The reaction was stirred at ambient temperature for 1 hour and poured into a separatory funnel. The layers were separated and the aqueous phase was extracted with methylene chloride (300 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated at reduced pressure. The resulting solid was suspended in ethanol (2 L), treated with concentrated ammonium hydroxide (1.5 L), and stirred at room temperature for two days. The reaction was concentrated at reduced pressure to remove most of the ethanol and extracted with methylene chloride (2 x 1 L). The combined organics were dried over anhydrous sodium sulfate, filtered and concentrated. The residue was triturated with ethyl ether and the solid collected and dried overnight in vacuo. MP. 179-180°C. *H NMR CDC13, δ 9.73 (br s, IH), 7.65-7.10 (m, 9H), 4.35 (br s, 2H).
1. Bock, M. G.; Dipardo, R. M.; Evans, B. E.; Rittle, K. E.; Veber, D. F.; Freidinger, R. M. J. Org. Chem., 1987, 52, 939-942.
Step G: 2,3-Dihydro- l -(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-lH-
1 ,4-benzodiazepine
A solution of 5-phenyl-l ,4-benzodiazepine-2-one (50 g,
0.21 1 mole) in DMF (100 mL) was treated with cesium carbonate (103.5 g, 0.317 mole) and trifluoroethyl iodide (109.7 g, 0.525 mole). The mixture was stirred at 50°C-60°C overnight. The reaction mixture was then poured into water (2 L) and extracted with ethyl acetate (3 X 1 L). The combined ethyl acetate fractions were dried over anhydrous magnesium sulfate, filtered and concentrated at reduced pressure. The material was chromatographed on silica gel (1.5 Kg) eluting with 1 : 1 ethyl acetate/heaxane. The combined pure fractions were concentrated at reduced pressure. The residue was swished with warm ethyl ether, cooled and filtered to give the product. MP = 130-131°C; *H NMR CDC13, δ 7.65-7.60 (m, 2H), 7.60-7.45 (m, 5H), 7.40-7.20(m, 2H), 5.25 (dq, J = 14, 8.6 Hz, IH), 4.82(d, J = 10.5 Hz, IH), 4.15 (app sextet, J = 8.6 Hz, IH), 3.81 (d, J = 10.5 Hz, IH)
Step H: 3-Azido-5-phenyl-l-(2,2,2-trifluoroethyl)-lH- benzorel \ 1.41 diazepine
To a stirring solution of 5-phenyl-l-(2,2,2-trifluoroethyl)- lH-benzo[e}[l,4jdiazepine (66 g,0.209 mole) in THF (1200 mL) cooled to -78°C was added potassium tert-butoxide (229 mL of a 1 N solution in THF dropwise over 30 min. A solution of the anion was obtained. A solution of 2,4,6-triisopropylbenzenesulfonylazide (71 g, 0.229 mole) in THF (200 mL) was added over 20 min. This was stirred for 10 min, acetic acid (50 g, 48 ml,0.834 mole) was added and the reaction allowed to warm to ambient temperature over 4 hours. The reaction was poured into sat. NaHCθ3 (IL) and extracted with ethyl acetate (2 x 500 mL). The organic layers were combined, washed once with water then brine, dried with Na2Sθ4 and evaporated at reduced pressure. The residue was dissolved in THF (500 mL) and then filtered to give a solid which was discarded. The solution of crude azide was used without further purification. iH NMR CDC13, δ 7.70-7.26 (m,9H), 5.28-5.12 (m,lH), 4.63 (s,lH), 4.35-4.10 (m,lH). Step I: 3- Amino-5-phenyl- 1 -(2,2,2-trifluoroethyl)- 1 H- benzorell 1.41diazepine
To a stirring solution of 3-azido-5-pheny 1-1 -(2,2,2- trifluoroethyl)-lH-benzo[e][ l ,4]diazepine (crude from above) in 1.3 L THF was added triphenylphosphine (109 g, 0.417 mol) and water (150 mL). This was stirred overnight at ambient temperature The reaction was then concentrated under reduced pressure, taken up in IN HCl (1500 mL) , and extracted with ethyl ether (2 x 500 mL). The combined organics were back extracted with IN HCl (1 x 300 L) . The combined aqueous layers were back extracted with ethyl acetate (100 mL) and then basefied with sat. NaHCθ3 (100 mL) and 50% NaOH until pH=10. This was extracted with ethyl acetate (2 x 500 mL). The combined ethyl acetate fractions were dried over Na2S04, evaporated under reduced pressure and crystallized from ethyl ether to give the title compound as a powder. MP = 141-143°C; 1H NMR CDC13, δ 7.70-7.26 (m,9H), 5.28-5.12 (m,lH), 4.57 (s,lH), 4.35-4.10 (m,lH).
Step J: 2-(R)-2-amino-N-[3R-2-oxo-5-ρhenyl- 1 - (2,2,2- trifluoroethyl)-2,3-dihydro-lH-benzo[e][l,41diazepin-3- yl]-3-phenyl-propionamide and 2-(R)-2-amino-N-[3(S)-2- oxo-5-phenyl-l - (2,2,2-trifluoroethyl)-2,3-dihydro-lH- benzoielf 1 ,41diazepin-3-yll-3-phenyl-propionamide To a mixture of 3-amino-5-phenyl-l -(2,2,2-trifluoroethyl)- lH-benzo[el[l ,41diazepine (20.0 g, 60.3 mmol), Boc-D-phenylalanine (17.6 g, 66.3 mmol), l -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-chloride. (15.0 g, 78.4 mmol), and 1-hydroxybenztriazole hydrate (10.6 g, 78.4 mmol) was added DMF (200 mL) . This was stirred at ambient temperature for 2 h. The reaction was diluted with sat. NaHC03 (1 L) and extracted with ethyl acetate( 2 x 400 mL.) The combined organics were washed with 10% KHSO4 (1 x 400 mL), dried over Na2Sθ4, and evaporated to a foam. (40.91 g, >100%, contains residual ethyl acetate). This material was carried on without purification. To a stirred solution of 2-(tert-butoxycarbonylamino)-N- f 2-oxo-5-phenyl- 1 -(2,2,2-trifluoroethyl)-2,3-dihydro- 1 H- benzo[el[l ,4]diazepin-3-yll-3-phenylpropionamide in ethyl acetate (300mL) cooled with an ice bath was bubbled HCl gas for lh. The reaction temperature was kept below 10°C. The reaction was evaporated under reduced pressure, the residue taken up in ice cold sat. NaHC03 (700 mL) and ethyl acetate. (500 mL) The phases were separated and the aqueous extracted with ethyl acetate. (1 x 500 mL). The organic layers were combined, dried over Na2S04 and evaporated under reduced pressure. This was chromatographed over a 10 x 50 cm. silica column, eluted with 1 % methanokethyl acetate. The upper Rf spot was isolated and evaporated under reduced pressure to give the 2R,3R diastereomer as a solid. The lower Rf spot was isolated and evaporated under reduced pressure to give the 2(R),(3S) diastereomer as a solid. iH NMR CDC13, δ 8.94 (d, J=8.6Hz, IH), 7.65-7.10 (m, 9H), 5.64 (d, J=8.6 Hz, IH), 5.28-5.12 (m, IH), 4.57 (s, IH), 4.35-4.10 (m, IH) 3.71 (dd, J=9.8 and 3.9 Hz, IH), 3.34 ( dd, J=13.9 and 3.9 Hz,lH), 2.79 (dd, J=13.9 and 10.0 Hz, IH).
Step K: 3-(R)-(+)-3-amino-5-phenyl- 1 -(2,2,2-trifluoro- ethyl)-H- benzof el \ 1 ,41 diazepine
To a stirring solution of 2-(R)-2-amino-N-[3R-2- oxo-5-pheny 1- 1 - (2,2,2-trifluoroethyl)-2,3-dihydro- 1 H- benzo[e][l,41diazepin-3-yl]-3-phenyl-propionamide (13.6 g, 28.3 mmol) in methylene chloride (136 ml) was added phenyl isothiocynate (3.87 mL, 32.3 mmol). This was stirred overnight at ambient temperature. The reaction was cooled in ice, trifluoroacetic acid (27 mL, 0.283 mol) was added and the reaction allowed to warm to ambient temperature. After stirring at ambient temperature for 2.5 hours the reaction was evaporated under reduced pressure, chromatographed on silica gel (500 g) eluting with with 90:10:1:1 methylene chloride:methanol:acetic acid:water. The low Rf spot was collected and evaporated under reduced pressure with no heat. The residue was taken up in 600 mL methylene chloride and washed with 300 mL sat. NaHC03, 300mL water, dried over Na2Sθ4, evaporated under reduced pressure, and crystallized from ethyl acetate/hexanes to give 6.65 g of a powder. [ ]D = +72.9° (c = 0.7, MeOH), MP = 156-158°C; iH NMR CDC13, δ 7.70-7.26 (m,9H), 5.28-5.12 (m,lH), 4.57 (s,lH), 4.35-4.10 (m, lH).
Step L: 3S-(+)-3-Amino-5-phenyl-l-(2,2,2-trifluoro-ethyl)-H- benzoreiπ.41 diazepine
The title compound was prepared using the procedure decribed in step F using 2(R)-2-amino-N-[3(S)-2-oxo-5-phenyl-l-
(2,2,2-trifluoroethyl)-2,3-dihydro-lH-benzo[e][l,4]diazeρin-3-yl]-3- phenyl-propionamide.
Step M: 3(R)-3-{ l-(4-Cyanobenzyl)imidazol-5-yl-methylamino }- 5-phenyl- 1 -(2.2.2-trifluoroethyl)-H-benzof el f 1.41 diazepine To a mixture of 3(R)-(+)-3-amino-5-pheny 1- 1 -(2,2,2- trifluoroethyl)-H-benzo[e][ l,41 diazepine (from stepK) (99.8mg, 0.299mmol) the aldehyde ( from example 1, step E) (79.5mg, 0.376mmol) and 3A molecular sieves (324mg) in methanol (3ml) was added sodium cyanoborohydride (0.375ml of a IM solution in THF, 0.375mmol). The pH was adjusted to 5 by addition of acetic acid and the reaction stirred under argon for 48h at room temperature. The solids were removed by filtration and the filtrate partitioned between EtOAc and sat. NaHCθ3 solution, the organic extracts were dried (MgS04) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-l 8, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C29H23N6OF3-2.40 TFA-0.30H2O: C, 50.27; H, 3.25; N, 10.41. Found: C, 50.28; H, 3.23; N, 10.54. FAB HRMS exact mass calcd for C29H24N6OF3: 529.196369 MH+); found 529.196770. I H NMR CD3OD δ 8.91 ( I H, d, J=1.5Hz), 7.90-7.30( 14H, m), 5.73(2H, s), 5.20(l H,m), 4.66( 1H, s), 4.60(1 H, m), 4.24(1 H, d, J=5.0Hz) and 4.10(1H, d, J=5.0Hz) ppm.
EXAMPLE 2
Preparation of 3(S)-3-{ l-(4-Cyanobenzyl) imidazol-5-yl-methylamino- l -5-phenyl-l-(2.2.2-trifluoroethvπ-H-benzo[eiπ .41 diazepine.
To a mixture of 3S-(+)-3-amino-5-phenyl- l -(2,2,2- trifluoroethyl)-H-benzo[e][ l ,41 diazepine (from step L) (99.8mg, 0.299mmol), the aldehyde ( from Example 1 , step E ) (81.5mg, 0.386mmol) and 3A molecular sieves (324mg) in methanol (3ml) was added sodium cyanoborohydride (0.375ml of a IM solution in THF, 0.375mmol). The pH was adjusted to 5 by addition of acetic acid and the reaction stirred under argon for 48h at room temperature. The solids were removed by filtration and the filtrate partitioned between EtOAc and sat. NaHC03 solution; the organic extracts were dried (MgS04) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-l 8, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C29H23N6OF3'2.30 TFA-0.30H2O: C, 50.69; H, 3.28; N, 10.56. Found: C, 50.70; H, 3.26; N, 10.66. FAB HRMS exact mass calcd for C29H24N6OF3: 529.196369 MH+); found 529.195981.
!H NMR CD3OD 5 8.91 (IH, d, J=1.5Hz), 7.90-7.30(14H, m), 5.73( 2H, s), 5.19(lH,m), 4.65(1H, s), 4.60(1H, m), 4.24(1H, d, J=5.0Hz) and 4.10(1 H, d, J=5.0Hz) ppm. EXAMPLE 3
Preparation of 3(R)-3-[ l -(4-Cyanobenzyl)imidazol-5-yl-acetylamino] }- 5-phenyl-l -(2,2,2-trifluoroethyl)-H-benzo[e1[1.41 diazepine
Step A: lH-Imidazole-4- acetic acid methyl ester hydrochloride
A solution of lH-imidazole-4-acetic acid hydrochloride (4.00g, 24.6 mmol) in methanol (100 ml) was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature (RT) for 18hr. The solvent was evaporated in vacuo to afford the title compound as a solid. iH NMR CDC13, δ 8.85(lH,s),7.45(lH,s), 3.89(2H,s) and 3.75(3H,s) ppm.
Step B: 1 -(Triphenylmethyl)- lH-imidazol-4-ylacetic acid methyl ester
To a solution of the product from Step A (24.85g, 0.141mol) in dimethylformamide (DMF) (115ml) was added triethylamine (57.2 ml, 0.412mol) and triphenylmethyl bromide(55.3g, O.πimol) and the suspension was stirred for 24hr. After this time, the reaction mixture was diluted with EtOAc (1 1) and water (350 ml). The organic phase was washed with sat. aq. NaHCθ3 (350 ml), dried (Na2Sθ4) and evaporated in vacuo. The residue was purified by flash chromatography (Siθ2, 0-100% ethyl acetate in hexanes; gradient elution) to provide the title compound as a solid. IH NMR CDCI3, δ 7.35(1H, s), 7.31(9H,m), 7.22(6H,m), 6.76(1 H, s), 3.680H, s) and 3.60(2H, s) ppm.
Step C: [1 -(4-cyanobenzyl)- 1 H-imidazol-5-yl]acetic acid methyl ester
To a solution of the product from Step B (8.00g, 20.9mmol) in acetonitrile (70 ml) was added bromo-p-toluonitrile (4.10g, 20.92 mmol) and heated at 55°C for 3 hr. After this time, the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was heated at 55°C for 18hr. The reaction mixture was cooled to room temperature and evaporated in vacuo. To the residue was added EtOAc (70 ml) and the resulting precipitate collected by filtration. The precipitated imidazolium salts were combined, suspended in methanol (100 ml) and heated to reflux for 30 min. After this time, the solvent was removed in vacuo, the resulting residue was suspended in EtOAc (75ml) and the solid isolated by filtration and washed (EtOAc). The solid was treated with sat. aq. NaHCθ3 (300ml) and CH2C12 (300ml) and stirred at room temperature for 2 hr. The organic layer was separated, dried (MgS04) and evaporated in vacuo to afford the title compound as a solid.
IHNMR CDCI3, δ 7.65(1H, d, J=8.0Hz), 7.53(1H, s), 7.15(1H, d, J=8.0Hz), 7.04(1H, s), 5.24(2H, s), 3.62(3H, s) and 3.45(2H, s) ppm.
Step D: \ 1 -(4-CvanobenzylV lH-imidazol-5-yllacetic acid
A solution of [l-(4-cyanobenzyl)-lH-imidazol-5-yl]acetic acid methyl ester (4.44g, 17.4mmol ) in THF (100ml) and 1 M lithium hydroxide (17.4 ml, 17.4 mmol) was stirred at room temperature for 18 hr. 1 M HCl (17.4 ml) was added and the THF was removed by evaporation in vacuo. The aqueous solution was lyophilized to afford the title compound containing lithium chloride as a solid. iH NMR CD3OD, δ 8.22(1H, s), 7.74(1H, d, J=8.4Hz), 7.36(1H, d, J=8.4Hz), 7.15(1H, s), 5.43(2H, s) and 3.49(2H, s) ppm.
Step E: 3(R)-3-{ l-(4-Cyanobenzyl) iinidazol-5-yl-acety]amino} -5- phenyl- 1 -C2.2.2-trifluoroethyl)-H-benzofel \ 1.41 diazepine To a mixture of 3(R)-(+)-3-amino-5-phenyl- l -(2,2,2- trifluoroethyl)-H-benzo[el[l ,4] diazepine (from example 1 , step K) (100.5mg, 0.302mmol), [ l -(4-cyanobenzyl)-lH-imidazol-5-yl]acetic acid (from step D) (85.9mg, O.303mmol), HOOBT (60.4mg, O.37mmol) and triethylamine (0.10ml, 0.717mmol) in DMF (3ml) was added EDC (71mg, O.37mmol) and the reaction was stirred at room temperature for 24h. The reaction was diluted with EtOAc (50ml) and washed with sat. NaHC03 solution; the organic extracts were dried (Na2Sθ4) and the solvent evaporated in vacuo. The residue was purified by preparative
HPLC (C-18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C32H23N6θ2F3«1.60 TFA: C, 53.96 H, 3.36; N,
11.37. Found: C, 54.02 H, 3.36; N, 1 1.18.
FAB MS 557 (MH+).
IH NMR CD3OD δ 9.01 (lH, d, J=1.5Hz), 7.90-7.30(14H, m), 5.60
( 2H, s), 5.35(lH,m), 5.20(1H, m), 4.60(1H, m) and 3.86(2H,m) ppm.
EXAMPLE 4
Preparation of 3(S)-3-[l -(4-Cyanorjenzyl)imidazol-5-yl-acetylamino-]-5- phenyl-l-(2.2,2-trifluoroethyl)-H-benzoleiπ .41 diazepine
To a mixture of 3S-(+)-3-amino-5-pheny 1-1 -(2,2,2- trifluoroethyl)-H-benzo[el[l ,41 diazepine (from example 1 , step L) (46.3mg, 0.139mmol), [l-(4-cyanobenzyl)-lH-imidazol-5-yll acetic acid ( from example 5, step D) (39.4mg, 0.139mmol), HOOBT (29.1mg, 0.178mmol) and triethylamine (0.05ml, 0.36mmol) in DMF (1.4ml) was added EDC (32mg, 0.17mmol) and the reaction stirred at room temperature for 24h. The reaction was diluted with EtOAc (50ml) and washed with saturated NaHCθ3 solution, the organic extracts were dried (Na2Sθ4) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1% trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C32H23N6θ2F3« 50 TFA: C, 54.48H, 3.39 N, 11.55. Found: C, 54.49 H, 3.32; N, 1 1.42. FAB MS 557 (MH+).
IH NMR CD3OD δ 9.01 (IH, d, J=1.5Hz), 7.90-7.30(14H, m), 5.60(2H, s), 5.36(lH,m), 5.21(1H, m), 4.61(1H, m) and 3.86(2H,m) ppm. EXAMPLE 5
Preparation of 3(R,S)-3-[l-(4-Cyanobenzyl) imidazol-5-yl-acetylamino- l-5-phenyl-l-(4-methoxy benzvP-H-benzoleHT.41 diazepine To a mixture of 3(R,S)-amino-5-phenyl-l -(4 methoxybenzyl)-H-benzo[e][ l,41 diazepine (prepared as in example 1 , steps F-I using 4-methoxybenzyl bromide in place of trifluoroethyl iodide and potassium carbonate as base) (lOO.Omg, 0.269mmol), [l -(4- cyanobenzyl)-lH-imidazol-5-y 11 acetic acid ( from example 3 step D) (76.6mg, 0.270mmol), HOOBT (55.2mg, 0.338mmol) and triethylamine (0.090ml, 0.65mmol) in DMF (3.0 ml) was added EDC (63mg, 0.33mmol) and the reaction stirred at room temperature for 24h. The reaction was diluted with EtOAc (50ml) and washed with saturated NaHCθ3 solution; the organic extracts were dried (Na2S04) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C38H3θN6θ3«1.80 TFA, 0.15H2O: C, 59.26H, 4.03 N, 10.47. Found: C, 59.27 H, 4.01; N, 10.31. IH NMR CD3OD δ 9.02 (lH, s), 7.80-7.10(14H, m), 6.91(2H,d, J=9.7Hz), 6.62(2H, d, J=9.7Hz), 5.70-5.50(4H,m), 5.31 (lH,s), 3.90(2H,m), and 3.68(3H,s) ppm.
EXAMPLE 6
Preparation of 3(R)-3-[l-(4-Cyanobenzyl) imidazol-5-yl-acetylamino-1-
5-phenyl- 1 -(methyl -H-benzolel 11.41 diazepine
To a mixture of 3(R)-amino-5-phenyl- 1 -(methyl)-H- benzo[el[ l,4] diazepine (prepared as in example 1 , steps F-I using methyl iodide in place of trifluoroethyl iodide) (99.8mg, O.376mmol), [l-(4-cyanobenzyl)- lH-imidazol-5-yllacetic acid (from example 3, step D) (1 lO.Omg, O.388mmol), HOOBT (74.4mg, O.338mmol) and triethylamine (0.125ml, 0.897mmol) in DMF (4.0 ml), was added EDC (63mg, O.33mmol) and the reaction was stirred at room temperature for 24h. The reaction was diluted with EtOAc (50ml) and washed with saturated NaHC03 solution; the organic extracts were dried (Na2Sθ4) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder.
Anal. Calcd for C29H24N603-1.95TFA, 0.70H2O: C, 54.62H, 3.81 N, 11.62. Found: C, 54.64 H, 3.57; N, 1 1.47. FAB MS 489 (MH+). iH NMR CD3OD δ 9.02 (IH, d, J=1.7Hz), 7.80-7.30(14H, m), 5.61(2H,s), 5.24(lH,s), 3.90(1 H, d, J=17.4Hz), 3.85(1H, d, J=17.4Hz), and 3.50(3H,s) ppm.
EXAMPLE 7
Preparation of 3(R)-3-[ l-(4-Cyanobenzyl) imidazol -5 -yl-acetylamino-1- 5-(4-fluorophenyl- 1 -(2.2.2 trifluoroethyl H-benzolel I" 1.41 diazepine
To a mixture of 3(R)-amino-5-(4-fluorophenyl)-l -(2,2,2- trifluoroethyl)-H-benzo[eJ[l ,4] diazepine (prepared as in example 1 , steps E-I using 2-amino-4-'fluorobenzophenone in place of 2- aminobenzophenone), (lOO.lmg, 0.285 mmol), [l -(4-cyanobenzyl)- lH- imidazol-5-yl] acetic acid ( from example 3, step D) (80.9mg, 0.285mmol), HOOBT (58mg, 0.36mmol) and triethylamine (0.095ml, 0.68mmol) in DMF (3.0 ml) was added EDC (66mg, 0.34mmol), and the reaction stirred at room temperature for 24h. The reaction was diluted with EtOAc (50ml) and washed with saturated NaHCθ3 solution; the organic extracts were dried (Na2Sθ4) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Lyophilization afforded the title compound as a powder. Anal. Calcd for C30H22N6O3F4-1.50TFA, 0.15H2O: C, 52.97 H, 3.21 N, 1 1.23. Found: C, 52.96 H, 3.01 ; N, 1 1.22. FAB MS 575 (MH+). i H NMR CD3OD δ 9.02 ( IH, d, J=1.5Hz), 7.80-7.10(13H, m), 5.59(2H, s), 5.34(lH,s), 5.20(lH,m), 4.59(lH,m), 3.89(1H, d, J=17.3Hz) and 3.82(1H, d, J=17.3Hz) ppm.
EXAMPLE 8
Preparation of 3-[5-Oxo-pyrrolidine-2(S)-carbonylamino]-2,3-dihydro-
2-oxo-5-phenyl- 1 H - 1 ,4-benzodiazepine
A solution of 3-amino-2,3-dihydro-2-oxo-5-phenyl-lH -1 ,4 -benzodiazepine hydrogen bromide (142 mg, 0.426 mmol), prepared by sequential treatment of an aqueous acetonitrile solution of the 4-methoxybenzyl derivative from example 5 with ammonium cerium IV nitrate, potassium tartrate solution and HBr/acetic acid - ( )- pyroglutamic acid (60.2 mg, 0.466 mmol), EDC (91 mg, 0.473 mmol), HOBT (63.5 mg, 0.473 mmol), and diisopropylethylamine (0.082ml, 0.473 mmol) in DMF (5 ml) was stirred at room temperature for 1 hours. The resultant solution was concentrated in vacuo, and the residue partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The organic extract was washed with brine, dried, (MgS04), filtered, and concentrated. The residue was purified by preparative HPLC (C18, eluted with a 5:95 to 40:60 wateπacetonitrile). Lyophilization provided the titled compound as a 1 : 1 mixture of diastereomers. iH NMR DMSO δ 10.9 (two singlets, IH), 9.21 (two doublets, IH), 7.95 (two singlets, IH), 7.7-7.2 (m, 9H), 5,24 (m, IH), 4.31 (m, IH); FAB MS 363 (MH+);
Anal. Calcd for C20H 18N4O3 0.19 CF3COOH- 0.37 H2O: C, 62.65; H, 4.88; N, 14.34. Found: C, 62.66; H, 4.87; N, 14.59. EXAMPLE 9
Preparation of 3(R)-3-[l-(4-Cyanobenzyl) imidazol-5-yl-ethylamino-1- 5-phenyl-l -(2,2.2-trifluoroethyl)-H-benzoleiπ ,41 diazepine
Step A: Preparation of 5-[l-(4-Cyanobenzyl)-lH- imidazolyllethanol
To a stirred solution of the ester from example 3, step C, (1.50g, 5.88mmol), in methanol (20ml) at 0°C, was added sodium borohydride (l.Og, 26.3mmol) portionwise over 5 minutes. The reaction was stirred at 0°C for 1 hr and then at room temperature for an additional 1 hr. The reaction was quenched by the addition of sat.NH4Cl solution and the methanol evaporated in vacuo. The residue wsas partitioned between EtOAc and sat NaHCθ3 solution and the organic extracts dried (MgS04) and evaporated in vacuo. The residue was purified by chromatography (Siθ2, gradient elution 4 to 10% methanol in methylene chloride) to afford the title compound as a solid. iH NMR CDC13 δ 7.64(2H, d, J=8.2Hz), 7.57(1H, s), 7.11(2H, d, J=8.2Hz), 6.97(lH,s), 5.23(2H, s), 3.79(2H, t, J=6.2Hz), 2.66(2H, t, J=6.2Hz) ppm.
Step B: 5-(-l -(4-Cvanobenzyl)-imidazolvπethyl methanesulfonate A solution of 5-[l-(4-cyanobenzyl)-lH-imidazolyl]ethanol (0.500 g, 2.20 mmol) in methylene chloride (6 ml) at 0°C was treated with Hunig's base (0.460ml, 2.64mmol) and methane sulfonyl chloride (0.204ml, 2.64mmol). After 2 hours, the reaction was quenched by addition of saturated NaHCθ3 solution (50ml) and the mixture was extracted with methylene chloride (50ml), dried MgSθ4 and the solvent was evaporated in vacuo. The title compound was used without furthur purification.
IH NMR CDCl3 δ 7.69 (lH, s) 7.66(2H, d, J=8.2Hz), 7.15 (2H, d,J=8.2Hz), 7.04(1H, s), 5.24(2H, s), 4.31(2H, t, J=6.7Hz), 2.96(3H, s), and 2.88(2H, t, J=6.6Hz)ppm. Step C: 3(R)-3-f l-(4-Cyanobenzyl) imidazol-5-yl-ethylamino-}-5- phenyl-1 -(2.2.2-trifluoroethyD-H-benzo[e1f 1.41 diazepine A mixture of 3R-(+)-3-amino-5-phenyl-l -(2,2,2- trifluoroethyl)-H-benzo[el[l ,4] diazepine (from example 1 , step K) (99.5mg, 0.299mmol), 5-(-l -(4-Cyanobenzyl)-imidazolyl)ethyl methanesulfonate (from step B) (94.5mg, 0.309mmol), K2CO3 (108mg,
0.781mmol) and sodium iodide (185mg, 1.23mmol) in DMF (1.5ml) was stirred under argon at 55°C for 24h. Additional mesylate (93mg
0.30mmol) was added and heating continued for 24h. The reaction mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic extracts were dried (MgS04) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-
18, gradient elution, 95:5 to 5:95 Water: acetonitrile containing 0.1 % trifluoroacetic acid). Furthur purification by flash chromatography,
(Siθ2 eluting with 2.5%NH4θH in acetonitrile), conversion to the corresponding hydrochloride salt with gaseous HCl in EtOAc and evaporation of the solvent in vacuo afforded the title compound as a powder.
Anal. Calcd for C3θH25N6θF3«2.0HCl«1.20H2θ: C, 56.56 H, 4.65; N,
13.19. Found: C, 56.54; H, 4.78; N, 12.93.
FAB HRMS exact mass calcd for C30H26 6OF3: 543.212019MH+); found 543.212383.
} H NMR CD3OD δ 9.07 (IH, s), 7.90-7.30(14H, m), 5.63( 2H, s),
5.30-5.15(2H,m), 4.69(1H, m), 3.62(1H, dt, J=12.5 and 7.9Hz), 3.47-
3.38(1H, m) and 3.14(2H,t, J=7.9Hz) ppm.
EXAMPLE 10
Preparation of 3(S)-3-[ l-(4-Cyanobenzyl) imidazol-5-yl-ethylamino-l-5- ρhenyl-l -(2.2.2-trifluoroethyl -H-benzofeiπ .41 diazepine
A mixture of 3S-(+)-3-amino-5-phenyl-l -(2,2,2- trifluoroethyl)-H-benzolel[l,41 diazepine (from example 1 , step L), (102.5mg, 0.307 mmol) 5-(-l-(4-Cyanobenzyl)-imidazolyl)ethyl methanesulfonate ( from example 9, step B ) (93.0mg, 0.305 mmol), K2CO3 (107mg, 0.774mmol) and sodium iodide (184mg, 1.23mmol) in
DMF (1.5ml) was stirred under argon at 55°C for 24h. Additional mesylate (93mg 0.30mmol) was added and heating continued for 24h. The reaction mixture was partitioned between EtOAc and saturated NaHC03 solution; the organic extracts were dried (MgSθ4) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, gradient elution, 95:5 to 5:95 water: acetonitrile containing 0.1 % trifluoroacetic acid). Furthur purification by flash chromatography, (Siθ2 eluting with 2.5%NH4θH in acetonitrile), conversion to the corresponding hydrochloride salt with gaseous HCl in EtOAc and evaporation of the solvent in vacuo afforded the title compound as a powder.
Anal. Calcd for C3θH25N6θF3«2.20HCM.20H2θ: C, 55.92 H, 4.63; N, 13.04. Found: C, 55.93; H, 4.63; N, 12.54. FAB HRMS exact mass calcd for C30H26N6OF3: 543.212019MH+); found 543.212542. iH NMR CD3OD δ 9.08 (IH, d, J=1.3Hz), 7.90-7.30(14H, m), 5.64( 2H, s), 5.30-5.15(2H,m), 4.69(1H, m), 3.62(1H, dt, J=12.5 and 7.9Hz), 3.47-3.38(lH, m) and 3.15(2H,t, J=7.9Hz) ppm. EXAMPLE 1 1
In vitro inhibition of ras farnesyl transferase
Assays of farnesyl-protein transferase.
Partially purified bovine FPTase and Ras peptides (Ras- CVLS, Ras-CVIM and RAS-CAIL) were prepared as described by Schaber et al, J. Biol Chem. 265.14701-14704 (1990), Pompliano, et al, Biochemistry 57 :3800 (1992) and Gibbs et al, PNAS U.S.A. #6:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 μl containing 100 mM N-(2-hydroxy ethyl) piperazine- V'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM [3Hj-famesyl diphosphate ([3H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 μg/ml FPTase at 31 °C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB β-plate counter. The assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [3HJ-FPP was utilized during the reaction period. Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
Human FPTase was prepared as described by Omer et al, Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1 % (w/v) polyethylene glycol 20,000, 10 μM ZnCl2 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 μl of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme. The compounds of the instant invention described in Examples 1 -10 were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC50 of < 100 μM.
EXAMPLE 12
In vivo ras famesylation assay
The cell line used in this assay is a v-ras line derived from either Ratl or NIH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. et al, Cancer Research 57:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37 °C, the cells are labelled in 3 ml methionine-free DMEM supple- meted with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[35s]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeρtin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are bought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y 13-259 (Furth, M.E. et al, J. Virol. 43:294-304, (1982)). Following a 2 hour antibody incubation at 4°C, 200 ml of a 25% suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X- 100.0.5% deoxycholate/0.1 %/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein. EXAMPLE 13
In vivo growth inhibition assay
To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Ratl cells transformed with either a v-ras, v-raf, or v-mos oncogene is tested. Cells transformed by v-Raf and v-Mos maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.
Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x IO4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1 % methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay). The cells are fed twice weekly with 0.5 ml of medium A containing 0.1 % memanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula
wherein:
Rb is selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, , R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, -N(R10)2, or R1 1OC(O)NR10-,
c) unsubstituted or substituted C1 -C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R11S(O)m-, R10C(O)NR10-, (R 10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R1 a and R1 b are independently selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-,
R1 1OC(O)-, N3, -N(R10)2, or R1 1OC(O)NR10-, c) unsubstituted or substituted C1 -C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substiπited aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O)m-, R1 0C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R2 is selected from
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O)m-, R10C(O)NR10-, (R10)2N-C(O), CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
R3 is selected from a sidechain of a natural amino acid;
R4 and R4a are independently selected from:
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R 1 1S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-; R5 is selected from :
a) tetrazole,
b) CO2R 10, and
c) CONR10R10;
R6 and R6a are independently selected from:
a) hydrogen,
b) halogen,
c) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
R8 is selected from:
a) hydrogen,
b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl,
perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, NO2, R102N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3, -N(R10)2, or R11OC(O)NR10-, and c) C1-C6 alkyl unsubstituted or substituted by aryl,
heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NH-, CN, H2N- C(NH)-, R10C(O)-, R1 0OC(O)-, N3, -N(R10)2, or
R10OC(O)NH-;
R9 is selected from:
a) hydrogen,
b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-,
R1 1S(O)m-, R10C(O)NR10-, CN, NO2,
(R10)2N-C-(NR10)-, R10C(O)-, R1 1OC(O)-, N3,
-N(R10)2, or R1 1OC(O)NR10-, and c) C1-C6 alkyl unsubstimted or substituted by perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, (R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, or R 1 1 OC(O)NR10-; R10 is selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
R1 1 is selected from C1-C6 alkyl and aryl;
A1 and A2 are independently selected from: a bond, -CH=CH-, -CΞC-,
-C(O)-, -C(O)NR10-, -NR10C(O)-, O, -N(R10)-,
-S(O)2N(R10)-, -N(R10)S(O)2-, or S(O)m;
Q is selected from:
a) hydrogen,
b) unsubstituted or substituted aryl, unsubstituted or
substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, -N(R10)2, or R11OC(O)NR10-, c) unsubstituted or substituted C1 -C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R 11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)., R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
V is selected from:
a) hydrogen,
b) heterocycle,
c) aryl,
d) C1 -C20 alkyl wherein from 0 to 4 carbon atoms are
replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if A1 is S(O)m and V is not hydrogen if A1 is a bond, n is 0 and A2 is S(O)m;
W is selected from:
a) hydrogen,
b) CF3,
c) unsubstituted or substituted C1 -C8 alkyl wherein the
substitutent on the substituted C1-C8 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
d) unsubstituted or substituted C1 -C8 cycloalkyl wherein the substitutent on the substinαted C1 -C8 cycloalkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3, -N(R10)2, and R11OC(O)-NR10-;
e) unsubstituted or substituted heterocycle,
f) unsubstituted or substituted aryl, and
g) CON(R2)CR3R5,
or R4, R4a and W taken together are hydrogen;
X is -CH2-, -C(=O)-, or -S(=O)m-;
Z is a heterocycle; m is 0, 1 or 2;
n is 0, 1 , 2, 3 or 4;
p is 0, 1, 2, 3 or 4;
r is 0 to 5, provided that r is 0 when V is hydrogen; and u is 0 or 1; or the pharmaceutically acceptable salts thereof.
2. A compound as defined in Claim 1 wherein:
Rb is selected from: a) hydrogen, and
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, and R 1 1OC(O)-NR10-;
R3 is selected from the side chain of methionine, serine, glutamine, leucine and phenylalanine;
R4 and R4a are independently selected from:
a) hydrogen, and
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3, -N(R10)2, and R 1 1OC(O)-NR10-;
R5 is selected from:
a) CO2R10, wherein R10 is hydrogen or C1-C6 alkyl and b) CONR10R10, wherein R10 is hydrogen or C1-C6 alkyl;
Q is selected from: a) hydrogen,
b) substituted or unsubstituted aryl, C3-C10 cycloalkyl,
R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N -C(NR10)-, R10C(O)-, R1 1OC(O)-,
-N(R10)2, or R11OC(O)NR10-,
c) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 1OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-; and
X is -CH2- ; or the pharmaceutically acceptable salts thereof.
3. A compound which inhibits famesyl-protein transferase which is:
3(R)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-methylamino1-5-phenyl- 1- (2,2,2-trifluoroethyl)-H-benzo[el[1,4] diazepine;
3(S)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-methylamino]-5-phenyl- 1- (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine;
3(R)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-acetylaminol-5-phenyl-1- (2,2,2-trifluoroethyl)-H-benzo[e][1 ,4] diazepine;
3(S)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-acetylaminol-5-phenyl-1 - (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine; 3(R,S)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-acetylaminol-5-phenyl- 1 -(4- methoxy benzyl)-H-benzo[e][ 1 ,4] diazepine;
3(R)-3-[ 1 -(4-Cyanobenzyl)imidazol-5-yl-acetylaminol-5-phenyl-1 - (methyl)-H-benzo[e][1 ,4] diazepine;
3(R)-3-[1-(4-Cyanobenzyl) imidazol-5-yl-acetylamino]-5-(4- fluorophenyl-1-(2,2,2 trifluoroethyl)-H-benzo[e][1 ,4] diazepine;
3-[5-Oxo-pyrrolidine-2(S)-carbonylamino]-2,3-dihydro-2-oxo-5- phenyl-1H -1 ,4-benzodiazepine;
3(R)-3-[1 -(4-Cyanobenzyl)imidazol-5-yl-ethylaminol-5-phenyl-1-(2,2,2- trifluoroethyl)-H-benzo[e][1 ,4] diazepine; and
3(S)-3-[ 1-(4-Cyanobenzyl) imidazol-5-yl]-ethylamino]-5-phenyl-1 - (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine.
4. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.
5. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 2.
6. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 3.
7. A method for inhibiting famesyl-protein transferase which comprises administering to a mammal in need thereof a
therapeutically effective amount of a composition of Claim 4.
8. A method for inhibiting famesyl-protein transferase which comprises administering to a mammal in need thereof a
therapeutically effective amount of a composition of Claim 5.
9. A method for inhibiting famesyl-protein transferase which comprises administering to a mammal in need thereof a
therapeutically effective amount of a composition of Claim 6.
10. A method for inhibiting famesyl-protein transferase which comprises administering to a mammal in need thereof a
merapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a
therapeutically effective amount of a compound of the formula :
wherein:
Ra is
Rb is selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, , R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, -N(R10)2, or R1 1OC(O)NR10-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
R 1 a and R1 b are independently selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R10O-, R 1 1S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-,
R 10OC(O)-, N3, -N(R10)2, or R1 1OC(O)NR10-, c) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R2 is selected from
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R3 is selected from a sidechain of a natural amino acid; R4 and R4a are independently selected from:
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstimted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R5 is selected from :
a) tetrazole,
b) CO2R10, and
c) CONR10R10;
R6 and R6a are independently selected from:
a) hydrogen,
b) halogen,
c) unsubstituted or substimted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R10OC(O)-NR10-;
R8 is selected from:
a) hydrogen,
b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl,
perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, NO2, R10 2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, or R11OC(O)NR10-, and c) C1-C6 alkyl unsubstituted or substituted by aryl,
heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NH-, CN, H2N- C(NH)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, or
R10OC(O)NH-;
R9 is selected from:
a) hydrogen,
b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-,
R11S(O)m-, R10C(O)NR10-, CN, NO2,
(R10)2N-C-(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, or R1 1OC(O)NR10-, and
c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, or R11 OC(O)NR10-; R10 is selected from hydrogen, C1-C6 alkyl, benzyl and aryl; R1 1 is selected from C1-C6 alkyl and aryl;
A1 and A2 are independently selected from: a bond, -CH=CH-, -C≡C-,
-C(O)-, -C(O)NR10-, -NR10C(O)-, O, -N(R10)-,
-S(O)2N(R10)-, -N(R10)S(O)2-, or S(O)m;
Q is selected from:
a) hydrogen,
b) unsubstituted or substituted aryl, unsubstituted or
substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, -N(R10)2, or R1 1OC(O)NR10-, c) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, halogen C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
V is selected from:
a) hydrogen,
b) heterocycle,
c) aryl,
d) C1 -C20 alkyl wherein from 0 to 4 carbon atoms are
replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl,
provided that V is not hydrogen if A1 is S(O)m and V is not hydrogen if A1 is a bond, n is 0 and A2 is S(O)m;
W is selected from:
a) hydrogen,
b) CF3,
c) unsubstituted or substituted C1 -C8 alkyl wherein the
substitutent on the substituted C1 -C8 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1 (O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
d) unsubstituted or substituted C1 -C8 cycloalkyl wherein the substitutent on the substituted C1-C8 cycloalkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3, -N(R10)2, and R11OC(O)-NR10-;
e) unsubstituted or substituted heterocycle,
f) unsubstituted or substituted aryl, and
g) CON(R2)CR3R5,
or R4, R4a and W taken together are hydrogen; X is -CH2-, -C(=O)-, or -S(=O)m-;
Z is a heterocycle; m is 0, 1 or 2;
n is 0, 1 , 2, 3 or 4;
p is 0, 1, 2, 3 or 4;
r is 0 to 5, provided that r is 0 when V is hydrogen; and u is 0 or 1 ;
or the pharmaceutically acceptable salts thereof.
1 11 A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
12. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 5.
13. A method for treating cancer which comprises administering to a mammal in need mereof a therapeutically effective amount of a composition of Claim 6.
14. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula: wherein:
Ra is
Rb is selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, , R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, -N(R10)2, or R1 1OC(O)NR10-,
c) unsubstituted or substimted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstimted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R1 a and R1b are independently selected from:
a) hydrogen,
b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-,
R10OC(O)-, N3, -N(R10)2, or R1 1OC(O)NR10-, c) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstinited or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O )m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R2 is selected from
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1 S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
R3 is selected from a sidechain of a natural amino acid;
R4 and R4a are independently selected from:
a) hydrogen,
b) unsubstituted or substituted C1-C6 alkyl wherein the
substimtent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R 10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R11OC(O)-NR10-;
R5 is selected from :
a) tetrazole,
b) CO2R10, and
c) CONR10R10; R6 and R6a are independently selected from:
a) hydrogen,
b) halogen,
c) unsubstituted or substituted C1-C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-,
R1 1S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
R8 is selected from:
a) hydrogen,
b) aryl, heterocycle, cycloalkyl, alkenyl, alkynyl,
perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, NO2, R102N-C(NR10)-, R10C(O)-, R1 0OC(O)-, N3, -N(R10)2, or R11OC(O)NR10-, and c) C1-C6 alkyl unsubstituted or substituted by aryl,
heterocycle, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NH-, CN, H2N- C(NH)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, or
R10OC(O)NH-;
R9 is selected from:
a) hydrogen,
b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R10O-,
R 11S(O)m-, R10C(O)NR10-, CN, NO2,
(R10)2N-C-(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, or R1 1OC(O)NR10-, and
c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R10O-, R11S(O)m-, R10C(O)NR10-, CN, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, or R1 1 OC(O)NR10-; R10 is selected from hydrogen, C1-C6 alkyl, benzyl and aryl; R 11 is selected from C1-C6 alkyl and aryl;
A1 and A2 are independently selected from: a bond, -CH=CH-, -C≡C-,
-C(O)-, -C(O)NR10-, -NR 10C(O)-, O, -N(R10)-,
-S(O)2N(R10)-, -N(R10)S(O)2-, or S(O)m;
Q is selected from:
a) hydrogen,
b) unsubstituted or substituted aryl, unsubstituted or
substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN, NO2, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, -N(R10)2, or R1 1 OC(O)NR10-, c) unsubstituted or substituted C1 -C6 alkyl wherein the
substitutent on the substituted C1-C6 alkyl is selected from unsubstihited or substituted aryl, heterocyclic, halogen C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1 OC(O)-NR10-;
V is selected from:
a) hydrogen,
b) heterocycle,
c) aryl,
d) C 1 -C20 alkyl wherein from 0 to 4 carbon atoms are
replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl,
provided that V is not hydrogen if A1 is S(O)m and V is not hydrogen if A1 is a bond, n is 0 and A2 is S(O)m; W is selected from:
a) hydrogen,
b) CF3,
c) unsubstituted or substituted C1 -C8 alkyl wherein the
substitutent on the substituted C1 -C8 alkyl is selected from halogen, unsubstiπited or substituted aryl, heterocyclic, C3- C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N-C(O)-, CN,
(R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R10)2, and R1 1OC(O)-NR10-;
d) unsubstituted or substituted C1-C8 cycloalkyl wherein the substitutent on the substituted C1 -C8 cycloalkyl is selected from halogen, unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O-, R11S(O)m-, R10C(O)NR10-, (R10)2N- C(O)-, CN, (R10)2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, and R11OC(O)-NR10-;
e) unsubstituted or substituted heterocycle,
f) unsubstituted or substituted aryl, and
g) CON(R2)CR3R5,
or R4, R4a and W taken together are hydrogen;
X is -CH2-, -C(=O)-, or -S(=O)m-;
Z is a heterocycle; m is 0, 1 or 2;
n is 0, 1 , 2, 3 or 4;
p is 0, 1, 2, 3 or 4;
r is 0 to 5, provided that r is 0 when V is hydrogen; and u is 0 or 1;
or the pharmaceutically acceptable salts thereof.
15. A method for treating neurofibromin benign proliferative disorder which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
16. A method for treating blindness related to retinal vascularization which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
17. A method for treating infections from hepatitis delta and related vimses which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
18. A method for preventing restenosis which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
19. A method for treating polycystic kidney disease which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 4.
EP97917131A 1996-04-03 1997-03-31 Inhibitors of farnesyl-protein transferase Withdrawn EP0891337A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1459496P 1996-04-03 1996-04-03
GBGB9614316.9A GB9614316D0 (en) 1996-07-08 1996-07-08 Inhibitors of farnesyl-protein transferase
GB9614316 1996-07-08
PCT/US1997/005240 WO1997036879A1 (en) 1996-04-03 1997-03-31 Inhibitors of farnesyl-protein transferase
US14594P 2007-12-18

Publications (1)

Publication Number Publication Date
EP0891337A1 true EP0891337A1 (en) 1999-01-20

Family

ID=26309662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917131A Withdrawn EP0891337A1 (en) 1996-04-03 1997-03-31 Inhibitors of farnesyl-protein transferase

Country Status (5)

Country Link
EP (1) EP0891337A1 (en)
JP (1) JP2000507587A (en)
AU (1) AU2555997A (en)
CA (1) CA2250203A1 (en)
WO (1) WO1997036879A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9695198A (en) * 1997-10-17 1999-05-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU778005B2 (en) 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
JP2003523345A (en) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Succinoylamino carbocycles and heterocycles as inhibitors of Aβ protein production
JP2004508289A (en) 2000-04-03 2004-03-18 デュポン　ファーマシューティカルズ　カンパニー Cyclic lactams as inhibitors of Aβ protein production
EP1268433A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
JP2004500419A (en) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Substituted lactams as Aβ protein production inhibitors
NZ516746A (en) 2000-06-01 2004-02-27 Bristol Myers Squibb Pharma Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
CA2622592A1 (en) 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis c infection
BRPI0709909A2 (en) 2006-03-31 2011-07-26 Rubicon Res Private Ltd oral disintegration tablets
JP2010526825A (en) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
TWI530489B (en) * 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
TWI614238B (en) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
WO2014047374A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
EP2897942B1 (en) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
JP2015531792A (en) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Prodrugs of 1,4-benzodiazepinone compounds
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026723A2 (en) * 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9736879A1 *

Also Published As

Publication number Publication date
CA2250203A1 (en) 1997-10-09
AU2555997A (en) 1997-10-22
JP2000507587A (en) 2000-06-20
WO1997036879A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
US5998407A (en) Inhibitors of farnesyl-protein transferase
EP0891337A1 (en) Inhibitors of farnesyl-protein transferase
US5919785A (en) Inhibitors of farnesyl-protein transferase
US5859012A (en) Inhibitors of farnesyl-protein transferase
US5869682A (en) Inhibitors of farnesyl-protein transferase
US5914341A (en) Inhibitors of farnesyl-protein transferase
AU715603B2 (en) Inhibitors of farnesyl-protein transferase
US5885995A (en) Inhibitors of farnesyl-protein transferase
EP1003374A4 (en) Inhibitors of farnesyl-protein transferase
US5780492A (en) Inhibitors of farnesyl-protein transferase
AU712504B2 (en) Inhibitors of farnesyl-protein transferase
AU715667B2 (en) Inhibitors of farnesyl-protein transferase
US5624936A (en) Inhibitors of farnesyl-protein transferase
AU704792B2 (en) Inhibitors of farnesyl-protein transferase
AU2660797A (en) Inhibitors of farnesyl-protein transferase
EP0891343A1 (en) Inhibitors of farnesyl-protein transferase
WO1997036593A1 (en) Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en) Inhibitors of farnesyl-protein transferase
WO1997036892A1 (en) Inhibitors of farnesyl-protein transferase
AU2555797A (en) Inhibitors of farnesyl-protein transferase
US5981562A (en) Inhibitors of farnesyl-protein transferase
WO1997036591A1 (en) Inhibitors of farnesyl-protein transferase
US5972942A (en) Inhibitors of farnesyl-protein transferase
WO1996031525A2 (en) Inhibitors of farnesyl-protein transferase
AU5428596A (en) Inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001002